Xu Guo-Qiang, Zhao Qi-Liang, Wang Xiao-Yu, Zhang Dong, Fan Shuang, Zhang Hui-Qi, Wang Mu-Tian, Chen Ming-Hu, Liu Min
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin 300193, China Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300193, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin 300193, China.
Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(4):1103-1113. doi: 10.19540/j.cnki.cjcmm.20210712.501.
At present, there have been many clinical trials and systematic reviews/Meta-analysis proving the good clinical efficacy of Shufeng Jiedu Capsules in the treatment of respiratory diseases, while comprehensive discussion is still required. This article overviews and analyzes the systematic reviews/Meta-analysis of Shufeng Jiedu Capsules to provide evidence support for clinical practice. The systematic reviews/Meta-analysis of Shufeng Jiedu Capsules were searched from CBM, Wanfang, CNKI, VIP, PubMed, EMbase and Cochrane Library. The AMSTAR 2 scale and GRADE system were respectively employed for the evaluation of methodological quality and the grading of evidence quality. Finally, 8 systematic reviews/Meta-analysis published during 2018-2021 were included for analysis. The diseases involved include acute exacerbation of chronic obstructive pulmonary disease, community-acquired pneumonia, acute tonsillitis, acute exacerbation of chronic bronchitis and acute upper respiratory tract infection. The number of included RCTs studies ranged from 8 to 25. The results showed that Shufeng Jiedu Capsules combined with western medicine routine had better therapeutic effect than the latter alone in the treatment of the above five diseases. The reported adverse reactions caused by Shufeng Jiedu Capsules were mainly gastrointestinal discomforts such as mild nausea, diarrhoea and vomiting, with low incidence and mild symptoms, which can be relieved by drug withdrawal. The methodological quality of the included studies was extremely low, and the outcome indicators were mainly of low and very low grades. The efficacy and safety of Shufeng Jiedu Capsules in the clinical treatment of diseases still need to be verified based on more high-quality studies. The relevant clinical research and systematic review/Meta-analysis should pay more attention to methodological quality and reporting standards and strengthen the scientificity of research.
目前，已有多项临床试验及系统评价/Meta分析证实疏风解毒胶囊治疗呼吸系统疾病具有良好的临床疗效，但仍需全面探讨。本文对疏风解毒胶囊的系统评价/Meta分析进行综述与分析，为临床实践提供证据支持。通过检索中国生物医学文献数据库（CBM）、万方数据库、中国知网（CNKI）、维普资讯（VIP）、PubMed、EMbase及Cochrane图书馆，获取疏风解毒胶囊的系统评价/Meta分析。分别采用AMSTAR 2量表和GRADE系统对方法学质量进行评价及对证据质量进行分级。最终纳入2018 - 2021年发表的8篇系统评价/Meta分析进行分析。所涉及疾病包括慢性阻塞性肺疾病急性加重、社区获得性肺炎、急性扁桃体炎、慢性支气管炎急性加重及急性上呼吸道感染。纳入的随机对照试验（RCT）研究数量为8至25项。结果显示，在治疗上述5种疾病时，疏风解毒胶囊联合西医常规治疗的疗效优于单纯西医常规治疗。疏风解毒胶囊报道的不良反应主要为轻度恶心、腹泻、呕吐等胃肠道不适，发生率低且症状较轻，停药后可缓解。纳入研究的方法学质量极低，结局指标主要为低质量和极低质量等级。疏风解毒胶囊在临床疾病治疗中的疗效和安全性仍需更多高质量研究加以验证。相关临床研究及系统评价/Meta分析应更加注重方法学质量和报告规范，加强研究的科学性。
